Literature DB >> 34399440

Pivotal role of phosphodiesterase 10A in the integration of dopamine signals in mice striatal D1 and D2 medium-sized spiny neurones.

Élia Mota1,2, Ségolène Bompierre1, Dahdjim Betolngar1, Liliana R V Castro1, Pierre Vincent1.   

Abstract

BACKGROUND AND
PURPOSE: Dopamine in the striatum plays a crucial role in reward processes and action selection. Dopamine signals are transduced by D1 and D2 dopamine receptors which trigger mirror effects through the cAMP/PKA signalling cascade in D1 and D2 medium-sized spiny neurons (MSNs). Phosphodiesterases (PDEs), which determine the profile of cAMP signals, are highly expressed in MSNs, but their respective roles in dopamine signal integration remain poorly understood. EXPERIMENTAL APPROACH: We used genetically encoded FRET biosensors to monitor at the single cell level the functional contribution of PDE2A, PDE4 and PDE10A in the changes of the cAMP/PKA response to transient and continuous dopamine in mouse striatal brain slices. KEY
RESULTS: We found that PDE2A, PDE4 and PDE10A operate on the moderate to high cAMP levels elicited by D1 or A2A receptor stimulation. In contrast, only PDE10A is able to reduce cAMP down to baseline in both type of neurones, leading to the dephosphorylation of PKA substrates. CONCLUSION AND IMPLICATIONS: In both MSN types, PDE10A inhibition blunts the responsiveness to dopamine, whereas PDE2A or PDE4 inhibition reinforces dopamine action.
© 2021 The British Pharmacological Society.

Entities:  

Keywords:  biosensing techniques; cAMP; cAMP-dependent protein kinase; dopamine; phosphodiesterases; striatum

Mesh:

Substances:

Year:  2021        PMID: 34399440     DOI: 10.1111/bph.15664

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  1 in total

1.  Inhibition of PDE10A-Rescued TBI-Induced Neuroinflammation and Apoptosis through the cAMP/PKA/NLRP3 Pathway.

Authors:  Jin Huang; Dang Tang; Yiqiang Cao; Yonggang Wang; Jiang Long; Lin Wei; Hai Song
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-12       Impact factor: 2.650

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.